Related Experiment Video
Updated: Jul 12, 2025
06:10
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
283
Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery
Theodora Katopodi1, Savvas Petanidis1,2, Doxakis Anestakis3
1Department of Medicine, Laboratory of Medical Biology and Genetics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pharmaceutics
|October 28, 2023
Summary
Nanotechnology offers solutions to challenges in chimeric antigen receptor (CAR) T cell therapy, enhancing its effectiveness against tumors. This approach improves CAR T cell delivery, persistence, and anti-tumor activity for better cancer treatment outcomes.
Area of Science:
- Immunotherapy
- Nanotechnology
- Oncology
Background:
- Chimeric antigen receptor (CAR) T cell therapy shows promise in treating hematological metastasis but faces challenges.
- Current limitations include toxicity, tumor accessibility, insufficient persistence, and manufacturing issues.
- Novel strategies are needed to overcome these hurdles and improve CAR T cell efficacy.
Purpose of the Study:
- To review the drawbacks of current CAR T cell immunotherapy.
- To explore the potential of nanotechnology in enhancing CAR T cell therapy.
- To discuss innovative applications of nanotechnology for clinical translation of CAR T cell treatments.
Main Methods:
- Review of existing literature on CAR T cell therapy and nanotechnology applications.
- Analysis of how nanotechnology can address CAR T cell limitations.
- Discussion of nanotechnology-driven strategies for CAR T cell engineering and function.
Main Results:
- Nanotechnology can facilitate CAR transgene delivery into T cells.
- It can enhance T cell expansion, trafficking, and intrinsic anti-tumor activity.
- Nanotechnology can help remodel immunosuppressive tumor microenvironments.
Conclusions:
- Nanotechnology presents a promising strategy to overcome CAR T cell therapy challenges.
- It enables genetic and functional modifications for more potent CAR T cells.
- Nanotechnology-supported CAR T cell therapy holds potential for improved anti-tumor efficacy and clinical translation.
